Department of Infectious Disease, Research and Prevention, Public Health Service Amsterdam, Amsterdam, The Netherlands.
Disease Elimination Program, Burnet Institute, Melbourne, Australia.
Harm Reduct J. 2021 Jan 6;18(1):2. doi: 10.1186/s12954-020-00444-6.
The Netherlands is well known for its early adoption of harm reduction (HR) programs at the height of its heroin crisis in the 1970s/1980s, including the implementation of the first needle and syringe program worldwide. In this manuscript, we describe how the Amsterdam Cohort Studies (ACS) among people who use drugs (PWUD) was conceived within the context of the Dutch HR approach, including the challenges scientists faced while establishing this cohort. This required striking a balance between public health and individual benefit, solving research dilemmas in the face of uncertainty, developing controversial innovative and cutting-edge interventions, which changed the prevention landscape for PWUD, and using longitudinal cohort data to provide unique insights. Studies from the ACS covering follow-up between 1985 and 2016 revealed that participation in both opioid agonist therapy and needle and syringe programs led to a major decrease in the risk of HIV and hepatitis B and C infection acquisition. ACS data have shown that the observed decrease in incidence also likely included shifts in drug markets and drug culture over time, selective mortality among those with the highest levels of risk behaviour, demographic changes of the PWUD population, and progression of the HIV and HCV epidemics. Moreover, HR programs in the Netherlands provided services beyond care for drug use, such as social support and welfare services, likely contributing to its success in curbing the HIV and viral hepatitis epidemics, increasing access and retention to HIV and HCV care and ultimately decreases in overdose mortality over time. Given the low coverage of HR programs in certain regions, it is unsurprising that continued HIV and HCV outbreaks occur and that transmission is ongoing in many countries worldwide. If we aim to reach the World Health Organization viral hepatitis and HIV elimination targets in 2030, as well as to improve the life of PWUD beyond infection risk, comprehensive HR programs need to be integrated as a part of prevention services, as in the Netherlands. We should use the evidence generated by longstanding cohorts, including the ACS, as a basis for which implementation and improved coverage of integrated HR services can be achieved for PWUD worldwide.
荷兰以在 20 世纪 70 年代/80 年代海洛因危机高峰期率先实施减少伤害 (HR) 计划而闻名,其中包括在全球范围内实施第一个针具和注射器计划。在本文中,我们描述了在荷兰 HR 方法的背景下,如何构思使用毒品者(PWUD)的阿姆斯特丹队列研究(ACS),包括科学家在建立该队列时面临的挑战。这需要在公共卫生和个人利益之间取得平衡,在面对不确定性时解决研究困境,开发有争议的创新和前沿干预措施,改变 PWUD 的预防格局,并利用纵向队列数据提供独特的见解。ACS 从 1985 年到 2016 年的随访研究表明,参与阿片类激动剂治疗和针具交换计划都大大降低了 HIV 和乙型肝炎和丙型肝炎感染的风险。ACS 数据表明,观察到的发病率下降也可能包括随着时间的推移,药物市场和药物文化的转变、风险行为最高水平的选择性死亡、PWUD 人群的人口变化以及 HIV 和 HCV 流行的进展。此外,荷兰的 HR 计划提供了超越药物使用护理的服务,例如社会支持和福利服务,这可能有助于其成功遏制 HIV 和病毒性肝炎的流行,增加 HIV 和 HCV 护理的机会和保留率,并最终随着时间的推移降低过量死亡率。鉴于某些地区 HR 计划的覆盖范围较低,继续发生 HIV 和 HCV 爆发以及在世界许多国家仍在发生传播也就不足为奇了。如果我们要在 2030 年实现世界卫生组织消除病毒性肝炎和 HIV 的目标,并改善 PWUD 的生活,除了感染风险之外,还需要将综合 HR 计划纳入预防服务,就像荷兰一样。我们应该利用包括 ACS 在内的长期队列产生的证据,作为在全球范围内为 PWUD 实现综合 HR 服务的实施和改善覆盖范围的基础。